CDD-3290 represents a highly specialized small molecule inhibitor specifically engineered to target the catalytic activity of Prostate-Specific Antigen (PSA/KLK3) with exceptional inhibitory potency. It effectively facilitates the measurable blockade of PSA-mediated proteolytic cleavage across various preclinical experimental models to evaluate the disruption of the tumor microenvironment during strictly monitored laboratory observation periods and enzyme kinetic assays to ensure high experimental sensitivity.